Chia Tai Tianqing Reports Phase III Results for TQB2102 in HER2-Low Breast Cancer at ESMO

Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical, reported pivotal Phase III results for its independently developed TQB2102 in HER2-low breast cancer, selected as a late-breaking abstract for a proffered paper session at ESMO. The abstract showed a median progression-free survival of 16.4 months with TQB2102 versus 5.5 months with comparator chemotherapy, an approximately 71% reduction in risk of disease progression or death, and a 2.2% incidence of treatment-related ILD.